HighTide Says Lead Drug Effective for NASH and Type2 Diabetes

HighTide Therapeutics, a Shenzhen-Maryland biopharma, published positive data from a US Phase II trial of its novel treatment for NASH and type 2 diabetes. HTD1801, a novel oral ionic salt of berberine and ursodeoxycholic acid combination, reduced liver fat while improving glycemic control and other cardiometabolic biomarkers. Patients were assessed after 18 weeks of treatment. The results were published online in Nature Communications. In May 2020, HighTide reported similar results from a China trial of HTD1801. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.